Kinases as Anti-Inflammatory Targets for Respiratory Disease

Author(s):  
Iain Kilty
2020 ◽  
Author(s):  
Jung-Kyu Lee ◽  
Bumjo Oh ◽  
Seo-Young Yoon ◽  
Tae Yun Park ◽  
Eun Young Heo ◽  
...  

Abstract Background HX110-A and HX110-B are compound extracts based on radix adenophorae and rhizoma dioscoreae, respectively, which have anti-inflammatory activity. There are limited data on whether they may help improve respiratory conditions including lung function. Therefore, in this trial, we will evaluate the effectiveness and safety of the use of HX110-A and HX110-B for the treatment of respiratory health in adults with mild respiratory symptoms. Methods/design This will be an 8-week, randomized, double-blind, parallel group, placebo-controlled trial with three arms. Adults more than 40 years old with persistent respiratory symptoms will be enrolled. Patients with definite respiratory disease or with a history of recent intake of antioxidants or anti-inflammatory agents will be excluded. Study subjects will be assigned at a 1:1:1 ratio into the following three arms: controls, experimental group 1 (HX110-A), and experimental group 2 (HX110-B). Control or experimental foods will be administered for 8 weeks, and follow-up will be up to 12 weeks. The primary outcome will be total antioxidant capacity. Secondary outcomes will be inflammatory indexes, respiratory symptoms, lung function, quality of life, and fatigue level. Safety outcomes will be assessed by monitoring adverse events and vital signs, and through clinical pathology tests. Conclusion We hope that this trial will reveal the effectiveness and safety of HX110-A and/or HX110-B for medical purposes in adults with respiratory symptoms. The results should clarify if active intake of specific foods with these functional compounds may promote respiratory health in adults without definite respiratory disease.


Marine Drugs ◽  
2020 ◽  
Vol 18 (11) ◽  
pp. 570
Author(s):  
Kate Summer ◽  
Jessica Browne ◽  
Lei Liu ◽  
Kirsten Benkendorff

Respiratory diseases place an immense burden on global health and there is a compelling need for the discovery of new compounds for therapeutic development. Here, we identify research priorities by critically reviewing pre-clinical and clinical studies using extracts and compounds derived from molluscs, as well as traditional molluscan medicines, used in the treatment of respiratory diseases. We reviewed 97 biomedical articles demonstrating the anti-inflammatory, antimicrobial, anticancer, and immunomodulatory properties of >320 molluscan extracts/compounds with direct relevance to respiratory disease, in addition to others with promising bioactivities yet to be tested in the respiratory context. Of pertinent interest are compounds demonstrating biofilm inhibition/disruption and antiviral activity, as well as synergism with approved antimicrobial and chemotherapeutic agents. At least 100 traditional medicines, incorporating over 300 different mollusc species, have been used to treat respiratory-related illness in cultures worldwide for thousands of years. These medicines provide useful clues for the discovery of bioactive components that likely underpin their continued use. There is particular incentive for investigations into anti-inflammatory compounds, given the extensive application of molluscan traditional medicines for symptoms of inflammation, and shells, which are the principal molluscan product used in these preparations. Overall, there is a need to target research toward specific respiratory disease-related hypotheses, purify bioactive compounds and elucidate their chemical structures, and develop an evidence base for the integration of quality-controlled traditional medicines.


2015 ◽  
Vol 5 (5) ◽  
pp. 392-398 ◽  
Author(s):  
Hacer Ilbilge Ertoy Karagol ◽  
Ozlem Yilmaz ◽  
Erdem Topal ◽  
Alper Ceylan ◽  
Arzu Bakirtas

2017 ◽  
Vol 5 (3) ◽  
pp. 842-845 ◽  
Author(s):  
Elsa Phillips-Angles ◽  
Pilar Barranco ◽  
Magdalena Lluch-Bernal ◽  
Javier Dominguez-Ortega ◽  
Valentín López-Carrasco ◽  
...  

Livestock ◽  
2020 ◽  
Vol 25 (6) ◽  
pp. 254-260
Author(s):  
Tim Potter

Bovine respiratory disease (BRD) is a complex syndrome that can cause significant economic impact on farm through the immediate costs of treatment as well as long-term production losses, and increased risk of mortality or premature departure from the herd. The clinical signs and pathology are due in part to the host's response to inflammatory mediators that are produced in reaction to the presence of the pathogens. Variation in individual animals' responses to the sepsis associated with BRD result in the spectrum of clinical signs and disease severity observed on farm. The variation in clinical picture presents a diagnostic challenge for farmers and can negatively impact disease detection. The use of objective scoring systems for BRD can facilitate the detection and provide a means of monitoring disease at a herd or group level. While antimicrobials remain the mainstay of BRD treatment on farm, the use of a non-steroidal anti-inflammatory drugs (NSAID) alongside them has become commonplace, with the aim of promoting more rapid recovery via their analgesic, anti-inflammatory and antipyretic actions.


Allergy ◽  
2016 ◽  
Vol 72 (4) ◽  
pp. 616-626 ◽  
Author(s):  
H. Y. Lee ◽  
Y. M. Ye ◽  
S. H. Kim ◽  
G. Y. Ban ◽  
S. C. Kim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document